Back to Search
Start Over
Point of care CYP2C19 genotyping after percutaneous coronary intervention.
- Source :
-
The pharmacogenomics journal [Pharmacogenomics J] 2022 Dec; Vol. 22 (5-6), pp. 303-307. Date of Electronic Publication: 2022 Apr 21. - Publication Year :
- 2022
-
Abstract
- Loss-of-function CYP2C19 variants are associated with increased cumulative ischemic outcomes warranting CYP2C19 genotyping prior to clopidogrel administration. TAILOR-PCI was an international, multicenter (40 sites), prospective, randomized trial comparing rapid point of care (POC) genotype-guided vs. conventional anti-platelet therapy. The performance of buccal-based rapid CYP2C19 genotyping performed by non-laboratory-trained staff in TAILOR-PCI was assessed. Pre-trial training and evaluation involved rapid genotyping of 373 oral samples, with 99.5% (371/373) concordance with Sanger sequencing. During TAILOR-PCI, 5302 patients undergoing PCI were randomized to POC rapid CYP2C19 *2, *3, and *17 genotyping versus no genotyping. At 12 months post-PCI, TaqMan genotyping determined 99.1% (2,364/2,385) concordance with the POC results, with 90.7-98.8% sensitivity and 99.2-99.6% specificity. In conclusion, non-laboratory personnel can be successfully trained for on-site instrument operation and POC rapid genotyping with analytical accuracy and precision across multiple international centers, thereby supporting POC genotyping in patient-care settings, such as the cardiac catheterization laboratory.Clinical Trial Registration: https://www.clinicalTrials.gov (Identifier: NCT01742117).<br /> (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
Details
- Language :
- English
- ISSN :
- 1473-1150
- Volume :
- 22
- Issue :
- 5-6
- Database :
- MEDLINE
- Journal :
- The pharmacogenomics journal
- Publication Type :
- Academic Journal
- Accession number :
- 35449399
- Full Text :
- https://doi.org/10.1038/s41397-022-00278-4